FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.479,89 +92,13 (+0,23%) Nasdaq
16.322,56 -23,71 (-0,15%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,30 -0,96 (-1,21%) Bitcoin EUR
55.976,14 -1.688,71 (-2,93%)
TSHA May 2024 1.500 call
| Chiusura precedente | 1,6000 |
| Aperto | 1,6000 |
| Denaro | 0,2500 |
| Lettera | 1,2500 |
| Prezzo d'esercizio | 1,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 1,6000 - 1,6000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireTaysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels,
- GlobeNewswire
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring Committee (IDMC) review Dosing of third adult patient and completion of enrollment in the low-dose cohort expected in the fourth quarter of 2023 Dosing of first pediatric Rett syndrome patient expected in the first quarter of 2024 DALLAS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (
- GlobeNewswire
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)
Following Type C meeting feedback from the U.S. FDA, Taysha is discontinuing development of TSHA-120 in GAN due to challenges with study design feasibility for potential Biologics License Application (BLA) submission Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development Strategic program prioritization will reduce operating expenses and is anticipated to extend cash runway into the fourth quarter of 2025 to support the continued
